Shopping Cart
- Remove All
- Your shopping cart is currently empty
Isatoribine(ANA245) free base is a potent TLR7 receptor agonist with anti-hepatitis C virus infection activity for the study of HCV infection.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $258 | In Stock | |
5 mg | $642 | In Stock | |
10 mg | $913 | In Stock | |
25 mg | $1,370 | In Stock | |
50 mg | $1,850 | In Stock | |
100 mg | $2,500 | In Stock |
Description | Isatoribine(ANA245) free base is a potent TLR7 receptor agonist with anti-hepatitis C virus infection activity for the study of HCV infection. |
In vivo | Isatoribine is a selective agonist of TLR7. In a proof-of-concept study, we found that once-daily 7-day treatment with intravenous Isatoribine 800 mg caused a significant (P = .001) reduction of plasma HCV RNA (mean, -0.76; range, -2.85 to +0.21 log(10) units) in otherwise untreated patients (n = 12) who were chronically infected with HCV. Viral load reduction occurred in patients infected with genotype 1 as well as non-genotype 1 HCV. The reduction of viral load was correlated with the induction of markers of a heightened immune antiviral state, including 2'-, 5'- oligoadenylate synthetase levels in whole blood. This treatment was well tolerated, with a low frequency of mild to moderate adverse events. In conclusion, systemic administration of the selective TLR7 agonist Isatoribine resulted in dose-dependent changes in immunologic biomarkers and a statistically significant antiviral effect with relatively few and mild side effects.[1] |
Alias | Isatoribine monohydrate, Isatoribine free base, Isatoribine, Immusine, ANA-245, ANA245, ANA 245 |
Molecular Weight | 316.29 |
Formula | C10H12N4O6S |
Cas No. | 122970-40-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (142.27 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.